Open AccessAutologous Bone Marrow‐Derived Mesenchymal Stromal Cells for the Treatment of Allograft Rejection After Renal Transplantation: Results of a Phase I Study
Author(s) -
Reinders Marlies E.J.,
de Fijter Johan W.,
Roelofs Helene,
Bajema Ingeborg M.,
de Vries Dorottya K.,
Schaapherder Alexander F.,
Claas Frans H.J.,
van Miert Paula P.M.C.,
Roelen Dave L.,
van Kooten Cees,
Fibbe Willem E.,
Rabelink Ton J.
Publication year - 2013
Publication title -
stem cells translational medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.781
H-Index - 71
eISSN - 2157-6580
pISSN - 2157-6564
DOI - 10.5966/sctm.2012-0114
Subject(s) - medicine , mesenchymal stem cell , immunosuppression , bone marrow , fibrosis , transplantation , calcineurin , subclinical infection , biopsy , pathology , urology , immunology
Mesenchymal stromal cells (MSCs) are an interesting candidate to aid in the long‐term survival of transplanted kidneys, because of their immunosuppressive and regenerative properties. This phase I study was the first to investigate the effects of MSCs in allograft rejection and fibrosis. Findings support the potential of MSCs as a novel cell therapy to prevent allograft rejection and interstitial fibrosis/tubular atrophy. The observed systemic immune suppression implies that careful monitoring of opportunistic viral infection is needed.